+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Plasma Protease C1-inhibitor Market Size, Share & Trends Analysis Report By Drug Class (C1-inhibitors, Kallikrein Inhibitor), By Dosage Form (Lyphophlised, Injectables), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • PDF Icon

    Report

  • 150 Pages
  • July 2024
  • Region: Global
  • Grand View Research
  • ID: 5990678
Description Jump to:
The global plasma protease C1-inhibitor market size is anticipated to reach USD 6.21 billion by 2030, expanding at a CAGR of 9.79% from 2024 to 2030, according to a new report. The global market for plasma protease C1-inhibitor is propelled by multiple pivotal factors such as the rising incidence of hereditary angioedema (HAE), a rare genetic disorder, increases the demand for effective therapies such as C1-inhibitor. Furthermore, advancements in biotechnology improve production efficiency, making these therapies more accessible.

Increased awareness and improved diagnosis of HAE and related conditions further contribute to substantial market growth. HAE affects approximately 1 in 50,000 individuals worldwide, underscoring the urgent need for therapies to alleviate symptoms and improve patient quality of life. Furthermore, advancements in biotechnology have enabled the development of recombinant products, which promise enhanced efficacy and accessibility for patients globally. These drivers are pivotal in shaping the landscape of the C1-INH industry, facilitating greater adoption and investment in novel treatment options.

Innovations in therapies are set to redefine treatment standards across various conditions. For instance, the introduction of long-acting formulations offers extended therapeutic effects, reducing treatment frequency and improving patient compliance. Additionally, ongoing research into new indications beyond HAE, such as antibody-mediated autoimmune diseases, showcases the versatility and potential of therapies in addressing unmet medical needs. These advancements underscore the dynamic nature of the industry, driven by continuous research and development efforts aimed at expanding therapeutic applications and optimizing patient outcomes.

Industry continues to expand; market players are increasingly focused on addressing key challenges and seizing opportunities for growth. Regulatory advancements and favorable reimbursement policies are anticipated to further propel market expansion, facilitating greater accessibility to C1-INH therapies for patients globally. Market players are leveraging these regulatory developments to streamline industry entry processes and ensure timely access to innovative treatments. Companies such as CSL Behring and Takeda Pharmaceutical are actively investing in expanding production capacities to meet escalating demand and ensure global supply chain resilience. Moreover, partnerships with research institutions and regulatory bodies are fostering innovation and accelerating the approval process for new C1-INH therapies. These proactive measures underscore a commitment to advancing treatment options and reinforcing market leadership, positioning stakeholders for sustained growth and success in the evolving healthcare landscape.

Plasma Protease C1-inhibitor Market Report Highlights

  • Based on drug class, C1-inhibitors dominated the market and accounted for the largest share in 2023. Selective bradykinin B2 receptor antagonist anticipated to grow at the fastest growth rate over the forecast period owing to undergoing R&D initiatives being undertaken by major players
  • Based on dosage form, the lyophilized segment held a dominant share in 2023 due to their stability, longer shelf life, and ease of storage and transportation, making them preferred for plasma protease C1-inhibitor therapies, ensuring efficacy and convenience for patients and healthcare providers alike
  • Based on distribution channel, hospital pharmacies dominated the market in 2023 due to their widespread accessibility, regulatory compliance, and ability to handle specialized therapies like plasma protease C1-inhibitor effectively
  • North America dominated the market and accounted for the largest share in 2023 owing to high healthcare spending, advanced healthcare infrastructure, robust research, and significant adoption of Plasma Protease C1-inhibitor therapies for various rare diseases like hereditary angioedema.


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Dosage form
1.2.3. Distribution Channel
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Drug Class and Dosage Form Snapshot
2.3. Distribution Channel Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Plasma Protease C1-inhibitor Market Variables, Trends, and Scope
3.1. Plasma Protease C1-inhibitor Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Disease Awareness
3.2.1.2. Advancements in Treatment Options
3.2.1.3. Expansion of Indications
3.2.2. Market Restraint Analysis
3.2.2.1. High Cost of Treatment
3.2.2.2. Side Effects and Safety Concerns
3.2.2.3. Regulatory Challenges
3.3. Plasma Protease C1-inhibitor Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTLE Analysis
Chapter 4. Plasma Protease C1-inhibitor Market Analysis, by Drug Class, 2018 - 2030 (USD Million)
4.1. Drug Class Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Plasma Protease C1-inhibitor Market by Drug Class Outlook
4.3.1. C1-inhibitors
4.3.1.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.2. C1-esterase Inhibitor
4.3.1.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.3. Recombinant Inhibitor
4.3.1.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2. Kallikrein Inhibitor
4.3.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3. Selective Bradykinin B2 Receptor Antagonist
4.3.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Plasma Protease C1-inhibitor Market Analysis, by Dosage Form, 2018 - 2030 (USD Million)
5.1. Dosage Form Market share, 2023 & 2030
5.2. Segment Dashboard
5.3. Plasma Protease C1-inhibitor Market by Dosage Form Outlook
5.3.1. Lyphophlised
5.3.1.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.2. Injectables
5.3.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Plasma Protease C1-inhibitor Market Analysis, by Distribution Channel, 2018 - 2030 (USD Million)
6.1. Distribution Channel Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Plasma Protease C1-inhibitor Market by Distribution Channel Outlook
6.3.1. Hospital Pharmacies
6.3.1.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2. Retail Pharmacies
6.3.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.3. Online Pharmacies
6.3.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Plasma Protease C1-inhibitor Market: Regional Estimates and Trend Analysis by Drug Class, by Dosage Form
7.1. Plasma Protease C1-inhibitor Market: Regional Outlook
7.2. North America
7.2.1. North America Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. U.S. Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2.3. Competitive/Market Scenario
7.2.2.4. Regulatory Framework
7.2.2.5. Reimbursement scenario
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Canada Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3.3. Competitive/Market Scenario
7.2.3.4. Regulatory Framework
7.2.3.5. Reimbursement Scenario
7.2.4. Mexico
7.2.4.1. Key Country Dynamics
7.2.4.2. Mexico Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4.3. Competitive/Market Scenario
7.2.4.4. Regulatory Framework
7.2.4.5. Reimbursement Scenario
7.3. Europe
7.3.1. Europe Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. UK Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2.3. Competitive/Market Scenario
7.3.2.4. Regulatory Framework
7.3.2.5. Reimbursement Scenario
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Germany Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3.3. Competitive/Market Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. Reimbursement Scenario
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. France Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4.3. Competitive/Market Scenario
7.3.4.4. Regulatory Framework
7.3.4.5. Reimbursement Scenario
7.3.5. Spain
7.3.5.1. Key Country Dynamics
7.3.5.2. Spain Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5.3. Competitive/Market Scenario
7.3.5.4. Regulatory Framework
7.3.5.5. Reimbursement Scenario
7.3.6. Italy
7.3.6.1. Key Country Dynamics
7.3.6.2. Italy Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6.3. Competitive/Market Scenario
7.3.6.4. Regulatory Framework
7.3.6.5. Reimbursement Scenario
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Denmark Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7.3. Competitive/Market Scenario
7.3.7.4. Regulatory Framework
7.3.7.5. Reimbursement Scenario
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Sweden Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8.3. Competitive/Market Scenario
7.3.8.4. Regulatory Framework
7.3.8.5. Reimbursement Scenario
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Norway Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9.3. Competitive/Market Scenario
7.3.9.4. Regulatory Framework
7.3.9.5. Reimbursement Scenario
7.4. Asia Pacific
7.4.1. Asia Pacific Plasma Protease C1-inhibitor Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Japan Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2.3. Competitive/Market Scenario
7.4.2.4. Regulatory Framework
7.4.2.5. Reimbursement Scenario
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. China Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3.3. Competitive/Market Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. Reimbursement Scenario
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. India Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4.3. Competitive/Market Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. Reimbursement Scenario
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Australia Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5.3. Competitive/Market Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. Reimbursement Scenario
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Thailand Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6.3. Competitive/Market Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Reimbursement Scenario
7.4.7. South Korea
7.4.7.1. Key Country Dynamics
7.4.7.2. South Korea Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7.3. Competitive/Market Scenario
7.4.7.4. Regulatory Framework
7.4.7.5. Reimbursement Scenario
7.5. Latin America
7.5.1. Latin America Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Brazil Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2.3. Competitive/Market Scenario
7.5.2.4. Regulatory Framework
7.5.2.5. Reimbursement Scenario
7.5.3. Argentina
7.5.3.1. Key Country Dynamics
7.5.3.2. Argentina Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3.3. Competitive/Market Scenario
7.5.3.4. Regulatory Framework
7.5.3.5. Reimbursement Scenario
7.6. MEA
7.6.1. MEA Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. South Africa Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2.3. Competitive/Market Scenario
7.6.2.4. Regulatory Framework
7.6.2.5. Reimbursement Scenario
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Saudi Arabia Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3.3. Competitive/Market Scenario
7.6.3.4. Regulatory Framework
7.6.3.5. Reimbursement Scenario
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. UAE Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4.3. Competitive/Market Scenario
7.6.4.4. Regulatory Framework
7.6.4.5. Reimbursement Scenario
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Kuwait Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5.3. Competitive/Market Scenario
7.6.5.4. Regulatory Framework
7.6.5.5. Reimbursement Scenario
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.2. Key Company Profiles
8.2.1. CSL
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Product benchmarking
8.2.1.4. Strategic initiatives
8.2.2. Takeda Pharmaceutical Company Limited
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Product benchmarking
8.2.2.4. Strategic initiatives
8.2.3. Pharming
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Product benchmarking
8.2.3.4. Strategic initiatives
8.2.4. KalVista Pharmaceuticals.
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Sanquin
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. BioCryst Pharmaceuticals, Inc.
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. CENTOGENE N.V.
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global protease C1-inhibitor market, by region, 2018 - 2030 (USD Million)
Table 4 Global plasma protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 5 Global plasma protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 6 Global plasma protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 7 North America protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
Table 8 North America protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 9 North America protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 10 North America protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 11 U.S. protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 12 U.S. protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 13 U.S. protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 14 Canada protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 15 Canada protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 16 Canada protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 17 Mexico protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 18 Mexico protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 19 Mexico protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 20 Europe protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
Table 21 Europe protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 22 Europe protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 23 Europe protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 24 Germany protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 25 Germany protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 26 Germany protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 27 UK protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 28 UK protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 29 UK protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 30 France protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 31 France protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 32 France protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 33 Italy protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 34 Italy protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 35 Italy protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 36 Spain protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 37 Spain protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 38 Spain protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 39 Denmark protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 40 Denmark protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 41 Denmark protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 42 Sweden protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 43 Sweden protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 44 Sweden protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 45 Norway protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 46 Norway protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 47 Norway protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 48 Asia Pacific protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
Table 49 Asia Pacific protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 50 Asia Pacific protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 51 Asia Pacific protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 52 China protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 53 China protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 54 China protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 55 Japan protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 56 Japan protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 57 Japan protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 58 India protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 59 India protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 60 India protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 61 South Korea protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 62 South Korea protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 63 South Korea protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 64 Australia protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 65 Australia protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 66 Australia protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 67 Thailand protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 68 Thailand protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 69 Thailand protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 70 Latin America protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
Table 71 Latin America protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 72 Latin America protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 73 Latin America protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 74 Brazil protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 75 Brazil protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 76 Brazil protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 77 Argentina protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 78 Argentina protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 79 Argentina protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 80 MEA protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
Table 81 MEA protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 82 MEA protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 83 MEA protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 84 South Africa protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 85 South Africa protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 86 South Africa protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 88 Saudi Arabia protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 89 Saudi Arabia protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 90 UAE protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 91 UAE protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 92 UAE protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
Table 93 Kuwait protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
Table 94 Kuwait protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
Table 95 Kuwait protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Plasma protease C1-inhibitor market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Drug class and dosage form segment snapshot
Fig. 11 Distribution channel segment snapshot
Fig. 12 Competitive landscape snapshot
Fig. 13 Global Pharmaceutical Market, (USD billion)
Fig. 14 Market dynamics
Fig. 15 Porter’s five forces analysis
Fig. 16 PESTLE analysis
Fig. 17 Plasma protease C1-inhibitor: Drug Class outlook and key takeaways
Fig. 18 Plasma protease C1-inhibitor market: Drug Class market movement analysis
Fig. 19 C1-inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 C1-esterase Inhibitor market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Recombinant Inhibitor market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Kallikrein Inhibitor market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Selective Bradykinin B2 Receptor Antagonist market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Plasma protease C1-inhibitor: Dosage form outlook and key takeaways
Fig. 25 Plasma protease C1-inhibitor market: Dosage form market movement analysis
Fig. 26 Lyphophlised market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Injectables market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Plasma protease C1-inhibitor: Distribution channel outlook and key takeaways
Fig. 29 Plasma protease C1-inhibitor market Distribution channel market movement analysis
Fig. 30 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Retail Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Online Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Plasma protease C1-inhibitor market revenue, by region, 2023 & 2030 (USD Million)
Fig. 34 Regional marketplace: Key takeaways
Fig. 35 Regional marketplace: Key takeaways
Fig. 36 North America plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Key country dynamics
Fig. 38 US plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Key country dynamics
Fig. 40 Canada plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Key country dynamics
Fig. 42 Mexico plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Europe plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Key country dynamics
Fig. 45 UK plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Key country dynamics
Fig. 47 Germany plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Key country dynamics
Fig. 49 France plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Key country dynamics
Fig. 51 Spain plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Key country dynamics
Fig. 53 Italy plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Key country dynamics
Fig. 55 Denmark plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Key country dynamics
Fig. 57 Sweden plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Key country dynamics
Fig. 59 Norway plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Rest of Europe plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Asia Pacific plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Key country dynamics
Fig. 63 Japan plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Key country dynamics
Fig. 65 China plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 China regulatory details
Fig. 67 India plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Key country dynamics
Fig. 69 Australia plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Key country dynamics
Fig. 71 Thailand plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 Key country dynamics
Fig. 73 South Korea plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 South Korea reimbursement scenario
Fig. 75 Rest of Asia Pacific plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 Latin America plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Key country dynamics
Fig. 78 Brazil plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Brazil regulation details
Fig. 80 Brazil reimbursement scenario
Fig. 81 Key country dynamics
Fig. 82 Argentina plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Argentina regulatory framework
Fig. 84 Rest of Latin America plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 85 Key country dynamics
Fig. 86 South Africa plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 87 Key country dynamics
Fig. 88 Saudi Arabia plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 89 Key country dynamics
Fig. 90 UAE plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 Key country dynamics
Fig. 92 Kuwait plasma protease C1-inhibitor market estimates and forecasts, 2018
Fig. 93 Rest of MEA plasma protease C1-inhibitor market estimates and forecasts,
Fig. 94 Company/competition categorization
Fig. 95 Company market share analysis, 2023
Fig. 96 Strategy mapping

Companies Mentioned

  • CSL
  • Takeda Pharmaceutical Company Limited
  • Pharming
  • KalVista Pharmaceuticals.
  • Sanquin
  • BioCryst Pharmaceuticals, Inc.
  • CENTOGENE N.V.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages150
PublishedJuly 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 3.33 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.21 Billion
Compound Annual Growth Rate9.7%
Regions CoveredGlobal
No. of Companies Mentioned7

Related Topics

Related Reports

Plasma Protease C1-Inhibitor Treatment Market by Drug Type, by Dosage, by Distribution Channel, and by Region - Product Image

Plasma Protease C1-Inhibitor Treatment Market by Drug Type, by Dosage, by Distribution Channel, and by Region

  • Report
  • 200 Pages
  • Global
From
Plasma Protease C1-Inhibitor Treatment - Global Strategic Business Report - Product Image

Plasma Protease C1-Inhibitor Treatment - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Plasma Protease C1-inhibitor Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Plasma Protease C1-inhibitor Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 78 Pages
  • Global
From
Plasma Protease C1 Inhibitor Market 2024-2028 - Product Image

Plasma Protease C1 Inhibitor Market 2024-2028

  • Report
  • 166 Pages
  • Global
From
Serine Proteases Global Market Report 2024 - Product Image

Serine Proteases Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From

About the C1 Inhibitor Market

The C1 Inhibitor market is a segment of the Immune Disorders Drugs market, which focuses on treatments for conditions related to the immune system. C1 Inhibitor is a protein that helps regulate the immune system and is used to treat a variety of conditions, including hereditary angioedema, a rare genetic disorder that causes swelling of the face, extremities, and airways. C1 Inhibitor drugs are used to reduce the frequency and severity of attacks, as well as to prevent them from occurring. C1 Inhibitor drugs are typically administered through subcutaneous injections, and are available in both branded and generic forms. The market is highly competitive, with a number of companies offering C1 Inhibitor drugs. Some of the major players in the market include Shire, CSL Behring, Pharming Group, and ViroPharma. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.